Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
43 hedge funds and large institutions have $17M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 20 reducing their positions, and 6 closing their positions.
0.08% more ownership
Funds ownership: 21.6% → 21.68% (+0.08%)
7% less funds holding
Funds holding: 46 → 43 (-3)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
35% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 20
73% less capital invested
Capital invested by funds: $64.1M → $17M (-$47.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$2.36M |
| 2 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$188K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$159K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$111K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$85.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$2.49M |
| 2 |
Morgan Stanley
New York
|
-$377K |
| 3 |
Millennium Management
New York
|
-$289K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$231K |
| 5 |
HF
HRT Financial
New York
|
-$170K |
ELOX Hedge Fund Activity: Q1 2020 in Review
43 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q1 2020, worth a combined $17M — down 73% from $64.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELOX and 4 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 13 added.
The largest buyer was Clal Insurance, adding an estimated $2.36M. The largest seller was Meitav Investment House, exiting entirely with an estimated $2.49M sold.
- 43 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q1 2020, down from 46 in Q4 2019.
- Funds reported $17M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q1 2020, down 73% quarter-over-quarter.
- 4 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 6 closed out, a net change of -2 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Clal Insurance, an estimated $2.36M added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Meitav Investment House, an estimated $2.49M sold.
Based on aggregated 13F filings for Q1 2020.